Sorrel to Open a New Manufacturing Facility
The new site will offer initial design and development, low-volume manufacturing, and scalable high-quality production of wearable drug delivery devices.
Sorrel Medical, an Israel-based developer and manufacturer of wearable drug delivery devices, announced on July 7, 2020 that it is opening a new manufacturing facility with cleanroom facilities to further scale its wearable drug delivery devices.
According to a company press release, the new site will offer initial design and development, low-volume manufacturing, and scalable high-quality production of wearable drug delivery devices. With the new 80-m2 cleanroom, the company will be able to increase its production capacity to hundreds of thousands of units per year.
“As Sorrel continues to grow, this new facility will enable us to support global pharmaceutical and biotechnology partners to bring next-generation drug delivery solutions to patients," said Bentsi Algazi, vice president of Operations at Sorrel, in the press release. "These enhanced production scale-up capabilities will enable us to positively impact countless patients living with chronic and high burden conditions."
Source: Sorrel
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
